|
2.5 ETIOLOGIE - GÉNOME
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
5.4.2 TRAITEMENTS - ECONOMIE - IQWIG
|
|
|
Ribociclib in breast cancer: added benefit for certain women after menopause [IQWIG]
|
|
|
|
|
|
According to the findings, an added benefit is not proven for initial endocrine therapy with ribociclib in combination with the aromatase inhibitor letrozole and for subsequent endocrine therapy with ribociclib plus fulvestrant. For initial endocrine therapy with ribociclib plus fulvestrant, in contrast, there is now an indication of a minor added benefit.
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|